BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 10554045)

  • 1. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
    Yu Z; Sefton J; Lew-Kaya D; Walker P; Yu D; Tang-Liu DD
    Clin Pharmacokinet; 2003; 42(10):921-9. PubMed ID: 12885265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tazarotene in the treatment of psoriasis.
    Marks R
    Br J Dermatol; 1999 Apr; 140 Suppl 54():24-8. PubMed ID: 10731131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris.
    Jarratt M; Werner CP; Alió Saenz AB
    Clin Drug Investig; 2013 Apr; 33(4):283-9. PubMed ID: 23456673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety of tazarotene in the treatment of plaque psoriasis.
    Marks R
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S25-32. PubMed ID: 9270553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging.
    Guenther LC
    Skin Therapy Lett; 2002 Mar; 7(3):1-4. PubMed ID: 12007011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tazarotene and acitretin in psoriasis.
    Heath MS; Sahni DR; Curry ZA; Feldman SR
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):919-927. PubMed ID: 30134735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging.
    Roeder A; Schaller M; Schäfer-Korting M; Korting HC
    Skin Pharmacol Physiol; 2004; 17(3):111-8. PubMed ID: 15087589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazarotene.
    Foster RH; Brogden RN; Benfield P
    Drugs; 1998 May; 55(5):705-11; discussion 712. PubMed ID: 9585866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis.
    Chandraratna RA
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S12-7. PubMed ID: 9270551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of tazarotene.
    Menter A
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S31-5. PubMed ID: 10898827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of topical tazarotene: a review.
    Talpur R; Cox K; Duvic M
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic profile of tazarotene.
    Duvic M
    Cutis; 1998 Feb; 61(2 Suppl):22-6. PubMed ID: 9787988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A status report on topical tazarotene in the management of acne vulgaris.
    Del Rosso JQ; Tanghetti E
    J Drugs Dermatol; 2013 Mar; 12(3):s53-8. PubMed ID: 23545935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans.
    Attar M; Yu D; Ni J; Yu Z; Ling KH; Tang-Liu DD
    J Pharm Sci; 2005 Oct; 94(10):2246-55. PubMed ID: 16136553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases.
    Kshirsagar SM; Shrestha N; Kipping T; Banga AK
    Eur J Pharm Biopharm; 2024 Jul; 200():114346. PubMed ID: 38823541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-selective retinoids for psoriasis: focus on tazarotene.
    Weindl G; Roeder A; Schäfer-Korting M; Schaller M; Korting HC
    Am J Clin Dermatol; 2006; 7(2):85-97. PubMed ID: 16605289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tazarotene gel: efficacy and safety in plaque psoriasis.
    Weinstein GD
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety review of tazarotene.
    Marks R
    J Am Acad Dermatol; 1998 Oct; 39(4 Pt 2):S134-8. PubMed ID: 9777791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.